ライフサイエンスコーパス: follicular lymphoma

1 refractory diffuse large B-cell lymphoma and follicular lymphoma.

2 patients with previously untreated advanced follicular lymphoma.

3 lerated and active in patients with relapsed follicular lymphoma.

4 ation of rituximab as maintenance therapy in follicular lymphoma.

5 er-derived diffuse large B-cell lymphoma and follicular lymphoma.

6 point blockade is worthy of further study in follicular lymphoma.

7 ous rituximab is a mainstay of treatment for follicular lymphoma.

8 mptomatic, advanced-stage, low-tumour-burden follicular lymphoma.

9 dy, with rituximab in patients with relapsed follicular lymphoma.

10 propagates clonal evolution toward malignant follicular lymphoma.

11 ed tyrosine peptides in Burkitt lymphoma and follicular lymphoma.

12 overdue watershed moment in the treatment of follicular lymphoma.

13 a new therapeutic option for advanced-stage follicular lymphoma.

14 slocation, which is strongly associated with follicular lymphoma.

15 udies have identified key genetic lesions in follicular lymphoma.

16 major breakpoint region (MBR) to cause human follicular lymphoma.

17 grade 3b follicular lymphoma, or transformed follicular lymphoma.

18 e development, progression, and treatment of follicular lymphoma.

19 ng opportunities to improve the treatment of follicular lymphoma.

20 beginning to unveil the molecular drivers of follicular lymphoma.

21 with rituximab-CVP (R-CVP) in patients with follicular lymphoma.

22 in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.

23 tcomes, and treatment options of early stage follicular lymphoma.

24 conditioning for relapsed and chemosensitive follicular lymphoma.

25 clinical trials in rheumatoid arthritis and follicular lymphoma.

26 may influence NHL etiology, particularly for follicular lymphoma.

27 cance of specific subsets of immune cells in follicular lymphoma.

28 I study in patients with untreated low-grade follicular lymphoma.

29 sponses and PFS are longer for patients with follicular lymphoma.

30 importance of the tumor microenvironment in follicular lymphoma.

31 ofiles provide targets for new therapies for follicular lymphoma.

32 d changes suggests specific risk factors for follicular lymphoma.

33 rash (four [50%] of eight) for patients with follicular lymphoma.

34 patients with newly diagnosed advanced-stage follicular lymphoma.

35 ypes, in particular mantle cell lymphoma and follicular lymphoma.

36 subtype, and 1 family displayed early-onset follicular lymphoma.

37 a (0 of 5), marginal zone lymphoma (0 of 6), follicular lymphoma (0 of 12), and diffuse large B-cell

38 ct test) but was present at low incidence in follicular lymphoma (1 of 81).

39 were diffuse large B-cell lymphomas (32.4%), follicular lymphomas (15.3%), classic Hodgkin lymphomas

40 in RRAGC uniquely enriched in patients with follicular lymphoma (17%).

41 Of 471 patients with stage I follicular lymphoma, 206 patients underwent rigorous sta

42 Of the 69 patients with primary follicular lymphoma, 38 (55%) presented with Ann Arbor s

43 ty patients were enrolled, including 34 with follicular lymphoma; 38 of 40 patients had previously re

44 esponse rate was 30%, including responses in follicular lymphoma (4 of 9) and DLBCL (2 of 5).

45 mas (MZLs), 2 lymphoplasmacytic lymphomas, 2 follicular lymphomas, 4 CLL/small lymphocytic lymphomas

46 Of 46 evaluable patients with follicular lymphoma, 40 (87%) patients had a complete re

47 For follicular lymphoma, 5-year net survival in northern Eur

48 95% CI, 18 to 71) and 10 of 14 patients with follicular lymphoma (71%; 95% CI, 42 to 92).

49 of indolent non-Hodgkin's lymphoma included follicular lymphoma (72 patients), small lymphocytic lym

50 mantle cell lymphoma (A051201) and relapsed follicular lymphoma (A051202).

51 The optimal management of stage I follicular lymphoma, according to consensus guidelines,

52 overall response rate (ORR) in patients with follicular lymphoma after induction and safety in patien

53 ty in both diffuse large B-cell lymphoma and follicular lymphoma, although the durability of response

54 We identified 13,988 follicular lymphoma and 25,320 diffuse large B-cell lymp

55 targeting EZH2 Y641 occur most frequently in follicular lymphoma and aggressive diffuse large B-cell

56 one of the most frequently mutated genes in follicular lymphoma and diffuse large B cell lymphoma; h

57 We considered follicular lymphoma and diffuse large B-cell lymphoma ca

58 Although survival for follicular lymphoma and diffuse large B-cell lymphoma is

59 report here that the two most common types--follicular lymphoma and diffuse large B-cell lymphoma--h

60 t lymphoma, nine BCL2 translocation-positive follicular lymphoma and four normal germinal center B ce

61 ogress in research and new therapies against follicular lymphoma and highlight the exciting opportuni

62 Although karyotypic events in follicular lymphoma and its transformation to aggressive

63 , undertaken at one instution, patients with follicular lymphoma and marginal zone lymphoma were give

64 Follicular lymphoma and multiple myeloma are clinically,

65 genetic evolution giving rise to relapse in follicular lymphoma and multiple myeloma, and discusses

66 a multicenter cohort study of patients with follicular lymphoma and subsequent biopsy-proven aggress

67 en studied most extensively in patients with follicular lymphoma and subsequent transformation to a d

68 vides new insights into the genetic basis of follicular lymphoma and the clonal dynamics of transform

69 ents with histologically documented relapsed follicular lymphoma and time to progression 6 months or

70 aneous rituximab to intravenous rituximab in follicular lymphoma and to provide efficacy and safety d

71 egion exhibiting an opposite risk effect for follicular lymphoma and type I diabetes.

72 ble patients had symptomatic, advanced stage follicular lymphoma and were previously untreated.

73 ing, which uncovered an ovarian carcinoma, a follicular lymphoma, and a Hodgkin lymphoma, each confir

74 hter's transformation, mantle cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia, w

75 itt's lymphoma, two of five with transformed follicular lymphoma, and four of eight with noncutaneous

76 compared with diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma.

77 Risks of chronic lymphocytic leukemia, follicular lymphoma, and mantle cell lymphoma were 5%-10

78 hocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma, expressed

79 om three B-NHL categories: Burkitt lymphoma, follicular lymphoma, and mantle-cell lymphoma.

80 s involving MYC in Burkitt lymphoma, BCL2 in follicular lymphoma, and MYC/BCL2/BCL6 in high-grade B-c

81 fuse large B-cell lymphoma, two patients had follicular lymphoma, and one patient had mantle cell lym

82 served for diffuse large B-cell lymphoma and follicular lymphoma, as well as marginal zone lymphoma f

83 eviously untreated grade 1-3a, CD20-positive follicular lymphoma at 67 centres in 23 countries.

84 We identified two variants associated with follicular lymphoma at 6p21.32 (rs10484561, combined P =

85 hts our current understanding of transformed follicular lymphoma biology and pathogenesis, current tr

86 alyse the mutation status of 74 genes in 151 follicular lymphoma biopsy specimens that were obtained

87 Although Burkitt lymphomas and follicular lymphomas both have features of germinal cent

88 CL), mantle-cell lymphoma (MCL), transformed follicular lymphoma, Burkitt's lymphoma, or noncutaneous

89 r immune responses can improve the course of follicular lymphoma, but might be diminished by immune c

90 We treated a patient with advanced follicular lymphoma by administering a preparative chemo

91 of diffuse large B-cell lymphoma and 41% of follicular lymphoma cases display genomic deletions and/

92 the complex interactions that occur between follicular lymphoma cells and the immune microenvironmen

93 ls of most measured signaling nodes, whereas follicular lymphoma cells represented the opposite patte

94 n multiple human B-cell lymphomas, including follicular lymphoma, chronic lymphocytic leukemia, mantl

95 as designed to explore the dose response for follicular lymphoma comparing 4 Gy in two fractions with

96 ased cohort of 107 patients with symptomatic follicular lymphoma considered ineligible for curative i

97 well as in non-Hodgkin lymphomas, including follicular lymphoma, diffuse large B-cell lymphoma, muco

98 e 40%, 36%, 15%, and 40% among patients with follicular lymphoma, diffuse large B-cell lymphoma, myco

99 and three occurred in those with transformed follicular lymphoma DLBCL (n=5).

100 y untreated, CD20-positive grade 1, 2, or 3a follicular lymphoma; Eastern Co-operative Oncology Group

101 Patients with early stage follicular lymphoma enjoy excellent outcomes following d

102 HL overall but was inversely associated with follicular lymphoma (ever smoking vs. never: hazard rati

103 oma (EMZL) (68.4% [180 of 263]), followed by follicular lymphoma (FL) (16.3% [43 of 263]), mantle cel

104 arginal-zone lymphoma (EMZL) (37% [n = 32]), follicular lymphoma (FL) (23% [n = 20]), diffuse large B

105 mutations in a large cohort of patients with follicular lymphoma (FL) (n = 366) and performed a longi

106 e colony-stimulating factor (GM-CSF) induces follicular lymphoma (FL) -specific immune responses.

107 d outcomes associated with transformation of follicular lymphoma (FL) among 2652 evaluable patients p

108 BBP is targeted by inactivating mutations in follicular lymphoma (FL) and diffuse large B-cell lympho

109 may play a role in the pathogenesis of human follicular lymphoma (FL) and other B cell malignancies.

110 In follicular lymphoma (FL) B cells, BCR expression is reta

111 es linked to surface immunoglobulin (sIg) of follicular lymphoma (FL) cells directly interact with en

112 We grew follicular lymphoma (FL) cells in vitro as multicellular

113 follicular lymphoma (PTNFL) is a variant of follicular lymphoma (FL) characterized by limited-stage

114 Follicular lymphoma (FL) constitutes the second most com

115 Most patients with follicular lymphoma (FL) experience multiple relapses ne

116 Twenty percent of patients with follicular lymphoma (FL) experience progression of disea

117 cl-2/IgH rearrangements can be quantified in follicular lymphoma (FL) from peripheral blood (PB) by p

118 of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) has been dramatically enhanced

119 Genome-wide association studies (GWASs) of follicular lymphoma (FL) have previously identified huma

120 Inherited risk determinants for follicular lymphoma (FL) have recently been described in

121 tion incidence and outcome for patients with follicular lymphoma (FL) in a prospective observational

122 0)Y) -ibritumomab tiuxetan in advanced-stage follicular lymphoma (FL) in first remission.

123 Follicular lymphoma (FL) is a B-cell neoplasm resulting

124 Follicular lymphoma (FL) is a B-cell tumor arising in ge

125 Follicular lymphoma (FL) is a clinically and molecularly

126 Follicular lymphoma (FL) is a clinically and molecularly

127 Follicular lymphoma (FL) is a clinically and molecularly

128 Follicular lymphoma (FL) is an indolent B-cell non-Hodgk

129 Purpose Follicular lymphoma (FL) is an indolent cancer, with eff

130 Follicular lymphoma (FL) is an indolent disease but tran

131 Follicular lymphoma (FL) is an indolent disorder that is

132 Follicular lymphoma (FL) is an indolent malignancy of ge

133 Follicular lymphoma (FL) is an indolent, yet incurable B

134 Follicular lymphoma (FL) is an uncurable cancer characte

135 Intraclonal heterogeneity in follicular lymphoma (FL) is apparent from studies of som

136 Follicular lymphoma (FL) is currently incurable using co

137 Advanced stage follicular lymphoma (FL) is incurable by conventional th

138 Follicular lymphoma (FL) is incurable with conventional

139 Follicular lymphoma (FL) is the most common form of indo

140 Follicular lymphoma (FL) is the most common form of indo

141 Follicular lymphoma (FL) is the most common indolent non

142 Follicular lymphoma (FL) is the most frequent indolent l

143 Follicular lymphoma (FL) is the second most common non-H

144 owever, the role of such lesions in indolent follicular lymphoma (FL) is unclear and individual lesio

145 rly death among those with high-tumor-burden follicular lymphoma (FL) is unsatisfactory with current

146 ated the impact of pretreatment vitamin D on follicular lymphoma (FL) outcome.

147 the role of rituximab maintenance in elderly follicular lymphoma (FL) patients after a brief first-li

148 The prognosis of follicular lymphoma (FL) patients is suspected to be inf

149 s a critical event in the clinical course of follicular lymphoma (FL) patients.

150 ic follicular lymphoma (PFL) is a variant of follicular lymphoma (FL) presenting as localized lymphad

151 Patients with follicular lymphoma (FL) registered in the F2-study and

152 Follicular lymphoma (FL) represents more than 20% of all

153 is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optima

154 Follicular lymphoma (FL) results from the accumulation o

155 The hallmark t(14;18)(q32;q21) in follicular lymphoma (FL) results in constitutive overexp

156 The follicular lymphoma (FL) T-cell microenvironment plays a

157 Transformation of follicular lymphoma (FL) to a more aggressive disease is

158 TAT3 in tumor-infiltrating T cells (TILs) in follicular lymphoma (FL) tumors, contrasting other non-H

159 of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) were calculated comparatively t

160 e follicular lymphoma (PTFL) is a variant of follicular lymphoma (FL) with distinctive clinicopatholo

161 atients enrolled, including 12 patients with follicular lymphoma (FL), 16 with diffuse large B-cell l

162 The microenvironment of human follicular lymphoma (FL), an incurable B cell non-Hodgki

163 Here, we investigated this scenario in follicular lymphoma (FL), an indolent GC-derived maligna

164 Follicular lymphoma (FL), an indolent neoplasm caused by

165 The vast majority of cases of follicular lymphoma (FL), but not normal B cells, acquir

166 ormed follicular lymphoma (TF) as opposed to follicular lymphoma (FL), diagnosing transformation earl

167 In follicular lymphoma (FL), follicular helper T cells (TFH

168 In low-tumor burden follicular lymphoma (FL), maintenance rituximab (MR) has

169 In follicular lymphoma (FL), malignant B cells are found ad

170 Patients with relapsed follicular lymphoma (FL), relapsed diffuse large B-cell

171 Follicular lymphoma (FL), the second most common type of

172 e the complete pathogenic circuitry of human follicular lymphoma (FL), which activates or decommissio

173 in diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL).

174 y reflect tumor biology and host response in follicular lymphoma (FL).

175 mide and rituximab (LR) are active agents in follicular lymphoma (FL).

176 ab tiuxetan ((90)Y-IT) as initial therapy of follicular lymphoma (FL).

177 itical early event in the natural history of follicular lymphoma (FL).

178 importance of the immune microenvironment in follicular lymphoma (FL).

179 t-line stand-alone therapy for patients with follicular lymphoma (FL).

180 ntation (HDC-ASCT) in patients with relapsed follicular lymphoma (FL).

181 nt in overall survival (OS) of patients with follicular lymphoma (FL).

182 to further characterize SNPs associated with follicular lymphoma (FL).

183 wn about the utility of PET in patients with follicular lymphoma (FL).

184 tments are required for rituximab-refractory follicular lymphoma (FL).

185 receptor A7 (EPHA7) as a tumor suppressor in follicular lymphoma (FL).

186 ial therapy for patients with advanced-stage follicular lymphoma (FL).

187 c lymphocytic leukemia (CLL; B-cell CLL) and follicular lymphoma (FL).

188 ently identified many new genetic lesions in follicular lymphoma (FL).

189 hronic lymphocytic B-cell leukemia (71%), in follicular lymphoma (FL, 70%), and in diffuse large B-ce

190 included mantle cell lymphoma (MCL; n = 28), follicular lymphoma (FL; n = 29), diffuse large B-cell l

191 antle cell lymphoma (MCL; n = 15), low-grade follicular lymphoma (FL; n = 44), hairy cell leukemia (H

192 Advanced follicular lymphomas (FL) are considered incurable with

193 For comparison, 16 follicular lymphomas (FLs), 9 extranodal marginal zone l

194 lymphomas (DLBCLs) and approximately 12% of follicular lymphomas (FLs).

195 nant treatment for patients with early stage follicular lymphoma for decades.

196 In phase 2, patients (age >/=18 years) with follicular lymphoma grades 1-3a were included.

197 ts (aged >/=18 years) with low-tumour-burden follicular lymphoma (grades 1, 2, and 3a) were randomly

198 ive, Ann Arbor stage II-IV DLBCL or grade 3b follicular lymphoma; had an Eastern Cooperative Oncology

199 p to 22% of germinal centre B-cell DLBCL and follicular lymphoma harbouring mutations at this site.

200 Follicular lymphoma has been shown to be highly radiosen

201 Follicular lymphoma has been somewhat neglected by the r

202 ients with advanced-stage, low-tumour-burden follicular lymphoma have conventionally undergone watchf

203 e progression-free survival in patients with follicular lymphoma; however, the optimal duration of ma

204 Recent insights into follicular lymphoma identify constitutional and environm

205 ons differentially methylated in Burkitt and follicular lymphomas implicated DNA methylation as coope

206 gh rate early for both lymphomas, except for follicular lymphoma in northern Europe.

207 2002-04 periods for both cancers (except for follicular lymphoma in Scotland and Wales and diffuse la

208 Follicular lymphoma in situ (FLIS) was first described n

209 re now available that target key pathways in follicular lymphoma including B-cell receptor signaling

210 both in combination, stratified by baseline follicular lymphoma International Prognostic Index (0-3

211 EF2B, EP300, FOXO1, CREBBP, and CARD11), the Follicular Lymphoma International Prognostic Index (FLIP

212 ients had stage III to IV disease, 37% had a Follicular Lymphoma International Prognostic Index (FLIP

213 for poor outcomes to first-line therapy (m7-Follicular Lymphoma International Prognostic Index [m7-F

214 Randomisation was stratified by Follicular Lymphoma International Prognostic Index risk

215 cyclophosphamide, vincristine, prednisone), Follicular Lymphoma International Prognostic Index score

216 ese patients was 61 years, 47% had high-risk Follicular Lymphoma International Prognostic Index score

217 "B" symptoms, histologic grade 3a, and high Follicular Lymphoma International Prognostic Index score

218 s and was stratified by country, gender, and Follicular Lymphoma International Prognostic Index score

219 ion was stratified by selected chemotherapy, Follicular Lymphoma International Prognostic Index, and

220 e intermediate or high risk according to the Follicular Lymphoma International Prognostic Index.

221 ndently of clinical variables, including the Follicular Lymphoma International Prognostic Index.

222 erapy-treated patients was additional to the Follicular Lymphoma International Prognostic Index.

223 Follicular lymphoma is a clinically and genetically hete

224 Follicular lymphoma is a monoclonal B-cell malignancy wi

225 Follicular lymphoma is a very common and still incurable

226 Follicular lymphoma is an incurable B cell malignancy ch

227 Follicular lymphoma is an incurable malignancy, with tra

228 Chemoimmunotherapy in follicular lymphoma is associated with significant toxic

229 with chemotherapy in patients with untreated follicular lymphoma is in progress.

230 The t(14;18) translocation in follicular lymphoma is one of the most common chromosoma

231 Minor changes (2.3%) mostly consisted of follicular lymphoma misgrading and diffuse large B-cell

232 Among patients with follicular lymphoma (n = 149), ORR seemed higher for obi

233 Patients presenting with stage IIIE-IV follicular lymphoma (n = 20) most frequently received ch

234 ipheral T-cell lymphoma (n = 8), transformed follicular lymphoma (n = 5), and Burkitt's (n = 1).

235 Patients with primary follicular lymphoma (n = 69) and those with isolated ocu

236 110 patients with follicular lymphoma (n=50), marginal zone lymphoma (n=30

237 Eighty-one patients were treated (follicular lymphoma, n = 10; diffuse large B-cell lympho

238 A and NHL subtypes include HLA-DRB1*0101 for follicular lymphoma (odds ratio [OR] = 2.14, P < .001),

239 , advanced stage (Ann Arbor stage III or IV) follicular lymphoma of WHO histological grades 1, 2, or

240 ynamics of cancer mortality in patients with follicular lymphoma or diffuse large B-cell lymphoma in

241 changed profoundly, benefiting patients with follicular lymphoma or diffuse large B-cell lymphoma.

242 or radical or palliative local control, with follicular lymphoma or marginal zone lymphoma, who had r

243 L; OR = 0.45, P = .006), and HLA-DRB1*13 and follicular lymphoma (OR = 0.48, P = .008).

244 with relapsed or refractory DLBCL, grade 3b follicular lymphoma, or transformed follicular lymphoma.

245 mab and lenalidomide in previously untreated follicular lymphoma (overall response rate [ORR] 90%-96%

246 nal zone lymphoma (P-interaction = 0.02) and follicular lymphoma (P-interaction = 0.04).

247 e B-cell lymphoma vs one of 15 patients with follicular lymphoma; P = .047) and with advanced stage d

248 encing on 10 follicular lymphoma-transformed follicular lymphoma pairs followed by deep sequencing of

249 slocations present in lymph node biopsies of follicular lymphoma patents.

250 For one follicular lymphoma patient, the recognized self-antigen

251 ss of radiation, the majority of early stage follicular lymphoma patients in the United States do not

252 and cellular immune responses in 50%-75% of follicular lymphoma patients, indicating that this thera

253 However, in 20% to 60% of follicular lymphoma patients, transformation to aggressi

254 ells from high-grade compared with low-grade follicular lymphoma patients.

255 Pediatric follicular lymphoma (PFL) is a variant of follicular lym

256 tinction of FLIS from partial involvement by follicular lymphoma (PFL).

257 Patients with ocular adnexal follicular lymphoma primarily treated with EBRT had a mo

258 Pediatric-type follicular lymphoma (PTFL) is a B-cell lymphoma with dis

259 Pediatric-type follicular lymphoma (PTFL) is a variant of follicular ly

260 Pediatric-type nodal follicular lymphoma (PTNFL) is a variant of follicular l

261 46, 95% confidence interval: 1.08, 1.97) and follicular lymphoma (rate ratio = 1.81, 95% confidence i

262 Previously untreated patients with follicular lymphoma received rituximab 375 mg/m(2) on da

263 s improves prognostication for patients with follicular lymphoma receiving first-line immunochemother

264 =18 years) patients with rituximab-sensitive follicular lymphoma relapsing after one to four previous

265 oking; P for trend = 0.03), particularly for follicular lymphoma (relative risk = 2.89 (95% CI: 1.23,

266 ted to be a reliable predictor of outcome in follicular lymphoma requiring treatment, and prospective

267 0 weeks, 60% and 36% of patients with CLL or follicular lymphoma, respectively, achieved objective re

268 7, 95% confidence interval: 1.12, 5.04) with follicular lymphoma risk.

269 Comparison of Burkitt and follicular lymphoma samples showed differential methylat

270 one lymphoma subtypes as well as age for the follicular lymphoma subtype.

271 ibility complex genetic variation influences follicular lymphoma susceptibility.

272 different treatment strategy for transformed follicular lymphoma (TF) as opposed to follicular lympho

273 tients with diffuse large B-cell lymphoma or follicular lymphoma that had relapsed or was refractory

274 tients with diffuse large B-cell lymphoma or follicular lymphoma that is refractory to or that relaps

275 Follicular lymphoma, the most common indolent subtype of

276 Histologic transformation of follicular lymphoma to an aggressive non-Hodgkin lymphom

277 rkitt lymphoma was more likely than indolent follicular lymphoma to express matriptase alone (86% ver

278 od for identifying bona fide contributors to follicular lymphoma transformation and may therefore gui

279 cific functional and genetic determinants of follicular lymphoma transformation remain elusive, and g

280 B-cell-specific regulatory model exhibiting follicular lymphoma transformation signatures using the

281 Therefore, to identify candidate drivers of follicular lymphoma transformation, we performed systema

282 whole-genome or whole-exome sequencing on 10 follicular lymphoma-transformed follicular lymphoma pair

283 3A and FCGR2A polymorphisms in patients with follicular lymphoma treated with rituximab and chemother

284 In patients with follicular lymphoma treated with single-agent rituximab,

285 tometry to profile single cells within human follicular lymphoma tumors and discovered a subpopulatio

286 vely enrolled group of patients with stage I follicular lymphoma, variable treatment approaches resul

287 ) with minimisation stratified by histology (follicular lymphoma vs marginal zone lymphoma), treatmen

288 01) plus chemotherapy in relapsed/refractory follicular lymphoma was explored in 56 patients.

289 (29.2%; P < .0001), whereas the frequency of follicular lymphoma was similar in Argentina (34.1%) and

290 8 years or older with Ann Arbor stage III-IV follicular lymphoma were assigned 1:1 to CVP plus intrav

291 ge B-cell lymphoma, mantle-cell lymphoma, or follicular lymphoma were enrolled.

292 relapsed, stable, or chemotherapy-resistant follicular lymphoma were treated with four doses of ritu

293 ree with mantle cell lymphoma and eight with follicular lymphoma) were enrolled.

294 A051201 (mantle cell lymphoma) and A051202 (follicular lymphoma) were phase 1 trials.

295 reated DLBCL, with no evidence of underlying follicular lymphoma, were investigated using immunohisto

296 (95% CI, 33 to 98) and 89% of patients with follicular lymphoma who had a response (95% CI, 43 to 98

297 mediastinal B-cell lymphoma, or transformed follicular lymphoma who had refractory disease despite u

298 rituximab is highly active in patients with follicular lymphoma who have received previous treatment

299 bendamustine, and rituximab in patients with follicular lymphoma whose disease was relapsed or refrac

300 nderwent autologous HSCT, 6 for MG and 1 for follicular lymphoma with coincident active MG.